caplacizumab
Sign in to saveCaplacizumab, sold under the brand name Cablivi, is a monoclonal antibody used for the treatment of thrombotic thrombocytopenic purpura. It is a von Willebrand factor-directed antibody fragment. It is given via intravenous injection followed by subcutaneous injection. Caplacizumab was developed by Ablynx NV.
In the Vinony graph
Vinony's link graph records 186 inbound references to caplacizumab, and connects out to intravenous infusion and defusion, hirudin and coagulation factor X.
Vinony files it under Chemicals that do not have a ChemSpider ID assigned, Drugs that are a monoclonal antibody and Drugs with non-standard legal status.
Vinony links it to 9 Wikipedia language editions.
Wikidata facts
- Subclass of
- chemical compound
- Has use
- medication
Show 2 more facts
- defined daily dose
- 10
- subject has role
- monoclonal antibody
Sources (1)
via Wikidata · CC0
~1 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Side effects
- Society and culture
- Legal status
- Economics
- Names
- Research
- References
- External links
Caplacizumab, sold under the brand name Cablivi, is a monoclonal antibody used for the treatment of thrombotic thrombocytopenic purpura. It is a von Willebrand factor-directed antibody fragment. It is given via intravenous injection followed by subcutaneous injection. Caplacizumab was developed by Ablynx NV.
Caplacizumab was authorized for medical use in the European Union in August 2018, and approved for medical use in the United States in February 2019. The US Food and Drug Administration considers it to be a first-in-class medication.
Excerpted from Wikipedia’s “caplacizumab” article, available under the CC BY-SA 4.0 licence.